Anti-NY-ESO-1 TCR-T cell theray (Shenzhen BinDeBio)

N/A

Report date: 2024/07/30 17:49:24

Base Information

Drug NameAnti-NY-ESO-1 TCR-T cell theray (Shenzhen BinDeBio)
Drug Alias NameAnti-NY-ESO-1 CAR-T cell therapy (Shenzhen BinDeBio)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionCancer/testis antigen 1 modulatorsGene transference
TargetsCancer/testis antigen 1
Therapy Area/IndicationsStomach NeoplasmsEsophageal NeoplasmsCarcinoma, Hepatocellular +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShenzhen Bindebio Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShenzhen Bindebio Ltd
Inactive CompaniesN/A
Active IndicationsStomach NeoplasmsEsophageal NeoplasmsCarcinoma, Hepatocellular +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A